Supernus to Present at Three Major Healthcare Conferences in March

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Supernus Pharmaceuticals will present at three major healthcare conferences in March 2026, updating investors on strategic initiatives and operational progress.

Supernus to Present at Three Major Healthcare Conferences in March

Supernus Pharmaceuticals announced its participation in three prominent healthcare investor conferences scheduled for March 2026. The company's management team will present at the TD Cowen 46th Annual Health Care Conference on March 2, the Jefferies Biotech on the Beach Summit on March 10, and the Barclays 28th Annual Global Healthcare Conference on March 11.

The conference presentations will provide institutional investors and industry analysts with updates on the company's strategic initiatives and operational progress. Select presentations will be accessible via live webcast, allowing broader participation from the investment community and other stakeholders unable to attend in person.

These appearances represent standard investor relations activity for publicly traded pharmaceutical companies, enabling direct engagement with capital markets participants during a concentrated period of healthcare-focused conference activity.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 23

Related Coverage

GlobeNewswire Inc.

Opus Genetics Earns Fast Company Innovation Recognition for Gene Therapy Pipeline

Clinical-stage biotech **Opus Genetics** named to Fast Company's 2026 most innovative companies list for gene therapy work in inherited retinal diseases.

IRD
GlobeNewswire Inc.

Zymeworks to Showcase Pipeline Progress at Major Healthcare Conferences

Zymeworks will present clinical and preclinical data at two major healthcare investor conferences in April, including the Needham Virtual Healthcare Conference and Bloom Burton & Co. event.

ZYME
GlobeNewswire Inc.

Serina Therapeutics to Showcase POZ Platform at Roth Conference

Clinical-stage biotech **Serina Therapeutics** will present at 38th Annual Roth Conference on March 24, 2026, highlighting its proprietary POZ Platform technology and pipeline.

PFESER
Benzinga

Outlook Therapeutics Launches Capital Raise Through Public Stock Offering

Outlook Therapeutics launches best-efforts public offering of stock and warrants with H.C. Wainwright as placement agent, subject to market conditions.

OTLK
GlobeNewswire Inc.

Inventiva to Report 2025 Results as MASH Drug Candidate Advances

Inventiva will release 2025 financial results March 30, 2026, while advancing lanifibranor in Phase 3 MASH trials.

IVA
GlobeNewswire Inc.

Inventiva to Report 2025 Results as MASH Drug Candidate Advances in Phase 3

Inventiva to release 2025 financial results March 30, 2026, as its lanifibranor MASH drug advances through Phase 3 clinical trials.

IVA